COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review

• Published in: International journal of molecular sciences Vol. 24; no. 11; p. 9231
• Main Authors: Bazylewicz, Marcin, Gudowska-Sawczuk, Monika, Mroczko, Barbara, Kochanowicz, Jan, Kułakowska, Alina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.05.2023; MDPI
• Subjects: Age; Antibodies; Antigens; Care and treatment; CD20 antigen; Cell-mediated immunity; Chronic illnesses; Comorbidity; Coronaviruses; COVID-19; COVID-19 vaccines; Disability; Disease transmission; Glucocorticoids; Health aspects; Hospitalization; Humans; Humoral immunity; Immune response; Immune system; Immunity, Cellular; Infections; Mortality; Multiple Sclerosis; Nervous system; Pathogens; Patients; Review; Risk; SARS-CoV-2; Serology; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; Vaccination; Viral infections; Poland; COVID-19; SARS-CoV-2; antibodies; immune response; multiple sclerosis; vaccination
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24119231

When the Coronavirus Disease 2019 (COVID-19) appeared, it was unknown what impact it would have on the condition of patients with autoimmunological disorders. Attention was focused on the course of infection in patients suffering from multiple sclerosis (MS), specially treated with disease-modifying therapies (DMTs) or glucocorticoids. The impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection on the occurrence of MS relapses or pseudo-relapses was important. This review focuses on the risk, symptoms, course, and mortality of COVID-19 as well as immune response to vaccinations against COVID-19 in patients with MS (PwMS). We searched the PubMed database according to specific criteria. PwMS have the risk of infection, hospitalization, symptoms, and mortality due to COVID-19, mostly similar to the general population. The presence of comorbidities, male sex, a higher degree of disability, and older age increase the frequency and severity of the COVID-19 course in PwMS. For example, it was reported that anti-CD20 therapy is probably associated with an increased risk of severe COVID-19 outcomes. After SARS-CoV-2 infection or vaccination, MS patients acquire humoral and cellular immunity, but the degree of immune response depends on applied DMTs. Additional studies are necessary to corroborate these findings. However, indisputably, some PwMS need special attention within the context of COVID-19.